动脉粥样硬化性心血管疾病（ASCVD）的防治始终是医学研究的焦点，而其中血脂异常的影响尤为关键。随着科研技术的不断进步，关于血脂的研究持续取得突破性进展，尤其是脂蛋白 (a)在ASCVD患者中的作用引起了广泛关注。在第74届美国心脏病学会年度科学会议（ACC.25）上，顶尖医学研究者们共同探讨了这一主题，分享了一系列令人振奋的研究成果，帮助临床医生在制定血脂异常患者的治疗方案时提供新的方向。

3月28日，据CDE官网消息，江西施美药业股份有限公司联合申请药品“贝派度酸片”，获得临床试验默示许可，受理号CYHL2500010。公示信息显示，药品“贝派度酸片”适应症：预防心血管疾病：降低最大耐受剂量他汀类药物治疗的成人发生心肌梗塞和冠状动脉血运重建的风险（包括未服用他汀类药物的患者）：确诊心血管疾病（CVD）； ...

Hyperlipidemia is a powerful and extremely common risk factor for cardiovascular disease (CVD), and it is clear that cholesterol-lowering therapy, with LDL-C as a primary target, is beneficial in ...

Orlistat-induced enhanced weight loss improves cardiovascular disease (CVD) risk factors. The drug decreases the LDL-cholesterol (LDL-C) levels to a greater degree than expected by weight loss alone.

Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Seeing high LDL numbers in your test results — ranging from 130 mg/dL to 190 mg/dL or higher, depending on your CVD risk — ...

Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside ...

Breastfeeding provides numerous health benefits for both infants and mothers. Beyond supporting infant nutrition and immunity ...